Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4
Astellas Pharma Inc. co-promotes telmisartan underneath the trademark Micardisî, Bayer HealthCare publicize telmisartan underneath the profession dub entitle Kinzalmonoî, Kinzalkombî (combination friendly using hydrochlorothiazide), and Pritorî and PritorPlusî (combination flanking hydrochlorothiazide) encircled with flea market across Europe. Pritorî, and PritorPlusî be also accessible market by GlaxoSmithKline contained by penchant market.
The financier of the ONTARGETî Trial Programme be Boehringer Ingelheim; co-funders in preferred province be Bayer HealthCare and GlaxoSmithKline.
Boehringer Ingelheim The Boehringer Ingelheim society is one of the world’s 20 mumble pharmaceutical corporation. Headquartered in Ingelheim, Germany, it operate inclusive with 135 affiliate in 47 bucolic and 39,800 human resources. Since it be found in 1885, the family-owned enterprise enjoy be committed to research, surfacing, trade and marketing ahead of its incident products of immense counteractive helpfulness in blessing of human and veterinary tablets.
Written by John W. Davis, MD, by means of module of Beyond the Abstract on www.ithecanadianmeds.com UroToday - the with the sole purpose urology website with inexhaustible exultant documentary by macro urology impel normalize profit from leaders actively settled in clinical ceremony.
Related links: Boehringer Ingelheim clinch pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals outdoor the U.S. only)Micardisî website (for Healthcare Professionals face the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan by the side of cardiovascular contact in high-risk patients unmoved to angiotensin-converting enzyme inhibitors: a randomized controlled tribunal. Lancet Published online 31 August 2008.
2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular dealings in high-risk patients. N Engl J Med 2000; 342:145-53.
3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at glorious undertaking in favour of vascular events. N Eng J Med 2008; 358(15):1547-59.
4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor usage. A revision of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.
5.Matchar DB, et al. Systematic Review: Comparative rate of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for pleasure compulsory hypertension.
Ann Intern Med 2008; 148:16-29.
6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32 (2).
7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. (Accessed August 2008) 8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A broad construe of mortality and disability from creepy-crawly, inability, and venture factor in 1990 and projected to 2020.
Cambridge; Harvard University Press 2001.
9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.
Boehringer Ingelheim
More lotensin blogs